Company news

Wuxi Biologics (Cayman) Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan

October 20, 2025

WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year

October 9, 2025

The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development

September 26, 2025

WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability

September 25, 2025

WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year

September 22, 2025

Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)

September 16, 2025

WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards

September 11, 2025

WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry

September 9, 2025

WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi

August 28, 2025

WuXi Biologics Reports Solid 2025 Interim Results

August 19, 2025

WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale

August 12, 2025

WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules

August 11, 2025

WuXi Biologics Named to A List for CDP Supplier Engagement Assessment

August 6, 2025

WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication

July 29, 2025

WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics

July 16, 2025

WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL

June 30, 2025

WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu

June 9, 2025

WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA

May 15, 2025

Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report

April 29, 2025

WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year

April 22, 2025

WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site

April 18, 2025

WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards

April 14, 2025

WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025

March 25, 2025

WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year

March 23, 2025

WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year

March 20, 2025

WuXi Biologics Included in S&P Global Sustainability Yearbook 2025

March 10, 2025

WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production

March 3, 2025

WuXi Biologics Again Passed GMP Inspection by Japan PMDA

February 27, 2025

WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year

February 18, 2025

← Newer news releases

Decks

The 5 newest of 25 decks. Every deck is listed under its year.